DBV Technologies SA - ADR - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
DBVT Nasdaq 2834 https://www.dbv-technologies.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for DBV Technologies SA - ADR

DBV Technologies to Participate in Upcoming Investor Conference - Sep 5th, 2023 8:30 pm
DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results - Jul 31st, 2023 8:25 pm
DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update - Jul 25th, 2023 8:30 pm
Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023 - Jul 19th, 2023 8:30 pm
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - Jul 10th, 2023 8:30 pm
Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2023 - Jun 16th, 2023 8:30 pm
DBV Technologies to Participate in Upcoming EAACI Congress 2023 - Jun 8th, 2023 8:30 pm
A simple skin patch shows promise for preventing peanut allergies - May 12th, 2023 3:21 pm
DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers - May 10th, 2023 9:30 pm
DBV Technologies Reports First Quarter 2023 Financial Results - May 4th, 2023 8:30 pm
DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA - Apr 19th, 2023 9:09 pm
DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting - Apr 12th, 2023 8:30 pm
Ordinary and Extraordinary General Meeting of April 12, 2023 - Mar 24th, 2023 8:30 pm
DBV Technologies Update - Mar 13th, 2023 5:30 am
DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years Old - Mar 7th, 2023 9:30 pm
DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document - Mar 2nd, 2023 10:30 pm
DBV Technologies Reports Full Year 2022 Financial Results and Business Update - Mar 2nd, 2023 9:30 pm
DBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023 - Feb 27th, 2023 6:30 am
DBV Technologies to Participate in Upcoming AAAAI 2023 Congress - Feb 21st, 2023 9:30 pm
Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2022 - Jan 4th, 2023 9:30 pm